Context: Acromegaly is a systemic disease characterized by persistent bone pathology and excess cardiovascular mortality. Despite multiple concomitant risk factors, atherosclerosis does not seem to be accelerated in acromegaly.
Intervention: MCCs were measured using flow cytometry based on the expression of osteocalcin (OC) and bone alkaline phosphatase (BAP) on monocytes and circulating CD34 + stem cells.
Main Outcome Measure: Differences in MCCs between patients and controls.
Results: OC + BAP + MCCs were severely reduced in acromegalic compared with control patients (0.17% 6 0.02% vs 1.00% 6 0.24%; P , 0.001), as were the total OC + and BAP + monocytic cells.
Patients with inactive acromegaly and those cured of acromegaly displayed persistently reduced levels of MCCs. In the controls, but not acromegalic patients, MCCs were increased in the presence of diabetes or cardiovascular disease. A direct correlation was noted between MCCs and parathyroid hormone (r = 0.61; P , 0.0001), supporting a link between bone biology and MCCs.
Conclusions: In patients with acromegaly, the levels of MCCs are reduced and remain low, even years after a complete cure. This finding might be related to low atherosclerotic calcification and the persistence of bone pathology after acromegaly remission or cure. (J Clin Endocrinol Metab 102: [2044] [2045] [2046] [2047] [2048] [2049] [2050] 2017) A cromegaly is a rare systemic disease caused by hypersecretion of growth hormone (GH). The morbidity of acromegaly results from its widespread multiorgan complications (1) , especially at the musculoskeletal, gastrointestinal, metabolic, and cardiovascular levels. In contrast, mortality is mainly related to cardiovascular disease or cancer (2, 3) .
Despite a high prevalence of cardiovascular risk factors, the most common cardiovascular manifestations in acromegaly are cardiac hypertrophy, valve disease, and arrhythmias (4) , and the association with atherosclerosis is less evident. Some studies have reported an increase in carotid intima-media thickness in acromegaly vs control patients (5, 6) , which was interpreted as a sign of premature atherosclerosis. However, the coronary calcium score, a marker of coronary atherosclerosis, has been shown to be lower in those with acromegaly compared with those without acromegaly (7) (8) (9) . In some patient populations, such as those with type 2 diabetes, plaque calcification is a marker for a future adverse cardiovascular prognosis (10) .
We have previously identified a population of procalcific monocytes with surface expression of osteocalcin (OC) and bone alkaline phosphatase (BAP). These socalled myeloid calcifying cells (OC + BAP + MCCs) are elevated in the blood of patients with diabetes or cardiovascular disease and promote ectopic calcification in vitro and in vivo (11) . When injected into atherosclerosisprone ApoE 2/2 mice, MCCs dramatically increased plaque calcification (12) . Also, wide evidence has shown that circulating procalcific cells are related to bone biology and intervene in the so-called bone-vascular axis [reviewed by Fadini et al. (13) ]. This is relevant because, in acromegaly, GH and insulin-like growth factor 1 (IGF-1) increase bone anabolism but result in a more generalized derangement of bone metabolism (14) . Therefore, we undertook an evaluation of circulating MCC levels in patients with active or inactive acromegaly, in patients cured of acromegaly, and in matched controls.
Materials and Methods

Patient enrollment and characterization
The local institutions approved the study, which was performed in accordance with the principles of the Declaration of Helsinki. All the participants provided written informed consent. We enrolled 44 consecutive acromegalic patients attending the Internal Medicine III of the Padua University Hospital from October 2014 to May 2016. Acromegaly was defined, in subjects presenting with typical clinical features, by high baseline serum GH levels (mean of 3 samples .2.5 mg/L) and/or no suppression with an oral glucose load (GH .0.4 mg/L), in association with high levels of IGF-1 (according to ageand sex-adjusted standard values) and evidence of a pituitary adenoma on magnetic resonance imaging. Patients who had recently (,3 months) undergone neurosurgery or radiation treatment, who had recently been hospitalized for a cardiovascular event, or who were in poor general condition were excluded. An additional group of 8 patients who had been completely cured of acromegaly was included. Complete cure was defined as successful treatment with neurosurgery with (n = 3) or without (n = 5) radiotherapy, plus medical therapy, and complete disease inactivity after withdrawal of the medications (15) . We enrolled 44 nonacromegalic control patients, who were matched to the sample patients by age, sex, and cardiovascular risk factors, from the outpatient clinic of the metabolic diseases division of the same hospital. All the patients underwent a standardized clinical evaluation, including medical history, anthropometric and vital parameters, and routine and endocrine blood tests. We collected the following data: age, sex, body mass index, prevalence of classic cardiovascular risk factors (diabetes, hypertension, smoking habit, and dyslipidemia), history of previous myocardial infarction or stroke (by reviewing the hospital medical records), and systolic and diastolic blood pressure. The presence and number of colonic polyps were recorded from the patient's medical records and colonoscopy results. Blood samples were drawn for the determination of the lipid profile, hemoglobin A1c (HbA1c), and procalcific cells (see later). All subjects also underwent a standard oral glucose tolerance test to detect abnormalities in carbohydrate metabolism. Finally, we collected data on the medications used.
Laboratory measures
Serum GH was measured using chemiluminescence with reagents supplied by GH IMMUNOLITE 2000 (Siemens, Munich, Germany). The detection limit was 0.05 mg/L, with an intra-and interassay variation coefficient of 4.0% and 6.5%, respectively. Serum IGF-1 was measured using chemiluminescence (DiaSorin, Saluggia, Italy). The detection limit was 0.6 mg/L, with an intra-and interassay variation coefficient of 5.6% and 7.7%, respectively. All other biochemical variables were assayed in plasma or serum using standard laboratory methods.
Flow cytometry
Analysis of circulating blood cells was performed as previously described (11) . In brief, fresh blood samples collected in the fasting state were analyzed within a few hours. After red blood cell lysis, the cells were stained with a fluorescein isothiocyanate-conjugated anti-CD34 monoclonal antibody (Becton Dickinson, Franklin Lakes, NJ), a phycoerythrinconjugated anti-OC monoclonal antibody (R&D Systems, Minneapolis, MN) and an allophycocyanin-conjugated anti-BAP, clone B4-78 (R&D Systems). For the analysis of MCCs, we first gated monocytes on the morphologic side-scattered light vs forward-scattered light plot and then examined this population for single and dual expression of OC and BAP. Representative examples of the gating strategy are shown in Fig. 1 . In a separate analysis, CD34 + cells were first gated in the mononuclear cell population, and the resulting population was examined for single and dual expression of OC and BAP. The same trained operator performed all the analyses throughout the study.
Statistical analysis
Data are presented as the mean 6 standard error, or as percentage, as appropriate. Non-normal variables were log transformed before analysis, and normality was checked using the Shapiro-Wilk test. Comparisons between two or more groups were performed using Student's t test or analysis of variance. Bonferroni's correction was applied to adjust for multiple testing. Linear correlations were checked using the Pearson's r coefficient, and regression coefficients were statistically compared using the Fisher z-transformation. Statistical significance was accepted at P , 0.05.
Results
Study population
The clinical characteristics of the patients and controls are listed in Table 1 . The controls were matched 1:1 with the patients with acromegaly for age, sex, and cardiovascular risk factors. Most (56.8%) of the patients had active disease, defined as an upper limit of normal of IGF-1 .1 (whether during treatment or not). All patients with inactive disease had an upper limit of normal IGF-1 level ,1 on at least two consecutive occasions. Some minor differences were found, including that patients with active acromegaly had significantly greater low-density lipoprotein cholesterol levels and a lower use of beta-blockers and platelet inhibitors compared with controls. No substantial differences were found among the acromegalic patients, except for the expected lower IGF-1 levels in inactive compared with active patients. The patients who had been cured of acromegaly had lower plasma glucose and HbA1c levels and a lower prevalence of cardiovascular disease.
Circulating MCC levels
The levels of circulating OC + BAP + MCCs were significantly reduced by .80% in acromegalic patients, irrespective of disease activity [0.17% 6 0.02% vs 1.00% 6 0.24%; P , 0.001; Figs. 1 and 2(a) ]. This was attributable to a reduction in both total OC staining [17.2% 6 2.9% vs 30.3% 6 4.3%; P = 0.012; Fig. 2(b) ] and total BAP staining [0.44% 6 0.06% vs 1.87% 6 0.32%; P , 0.0001; Fig. 2(c) ] on monocytes.
When the expression of OC and BAP was analyzed on circulating CD34
+ stem cells, we detected no difference between the acromegaly patients and controls [ Fig. 2(d) ], and acromegaly was not associated with changes in the levels of CD34 + cells, which were within the normal range We also analyzed the data from 8 patients who had been completely cured of acromegaly. Compared with the controls, these patients showed persistently reduced levels of OC + BAP + MCCs (0.26% 6 0.06%; P = 0.005), which were almost equivalent to the levels observed in patients with active or inactive disease [ Fig. 2(a) ]. OC + monocytes were still markedly reduced in the cured patients [ Fig. 2(b) ]; however, a substantial resurge in the percentage of BAP expression was observed, although the levels of BAP + cells were still lower in the cured patients than in the controls [ Fig. 2(c) ].
In the individuals without acromegaly, the MCCs were higher in the presence of cardiovascular disease [2.09% 6 0.56% vs 0.58% 6 0.21%; P = 0.004; Fig.  3(a) ] or type 2 diabetes [2.31% 6 0.60% vs 0.37% 6 0.08%; P , 0.0001; Fig. 3(b) ]. A direct correlation was noted with the fasting plasma glucose level (r = 0.42; P = 0.002) and HbA1c [r = 0.36; P = 0.011; Fig. 3(c) ]. All these associations were completely lost in the acromegalic patients [ Fig. 3(a-c) ], and the difference in the correlation coefficients for plasma glucose and HbA1c in the two groups was statistically significant. In the acromegaly group, the only statistically significant correlation of OC + BAP + MCC levels was with the concentrations of parathyroid hormone [PTH; r = 0.61; P , 0.0001; Fig. 3(d) ]. Data on colonic polyps were available for 35 patients. Patients with colonic polyps showed lower levels of MCCs than did patients without; however, the difference was far from statistical significance (0.14% 6 0.03% vs 0.20% 6 0.04%; P = 0.41). 
Discussion
In the present study, we surprisingly found that the levels of MCCs remained persistently low during the entire clinical history of acromegaly, even years after a complete cure. To the best of our knowledge, the present study is the first to report on circulating procalcific cell types in acromegaly and the first to clearly demonstrate a biological defect in circulating cells that persists after cure. The complete demodulation of MCCs in acromegaly is supported by the lack of any association with cardiovascular disease and diabetes, which was previously shown (11) and confirmed in our study in nonacromegalic individuals.
Compared with very rare populations of circulating cells with procalcific potential, such as mesenchymal stem cells and osteoprogenitors, MCCs are a relatively abundant cell population, representing ;1% of monocytes in healthy subjects (13) . Data indicate that MCCs reflect one of the many aspects of monocyte-macrophage plasticity (16) and are involved in several biological processes, including ectopic calcification (11, 12) , angiogenesis (17) , and bone remodeling (13) . Thus, our findings could have several important pathophysiological implications in acromegaly.
First, the depletion of circulating MCCs might explain why atherosclerotic calcification is lower in acromegalic patients than in controls (7) (8) (9) , despite the multiple cardiovascular risk factors and the possible acceleration of early atherosclerosis evaluated as carotid intima-media thickness (5, 6) .
Second, persistent depletion of MCCs even after the cure of acromegaly reflects the persistency in bone pathology, such as skull deformities (18) and osteophytosis (19) . The anabolic effect of GH on the skeleton is maintained long term after the successful treatment of acromegaly (20) . Because skeletal anabolism suppresses PTH concentrations (21) , the direct correlation we observed between MCCs and PTH supports a link between MCCs and bone status in acromegaly. Thus, although the interrelationships between monocyte and macrophage subtypes are difficult to establish, we speculate that MCCs might represent precursors of so-called OsteoMacs, osteal macrophages that regulate bone dynamics (22, 23) .
This scenario in the bone-vascular axis is complementary to what has been observed in osteoporosis, which is associated with vascular calcification and an excess of circulating procalcific cells (24) that can be counteracted by bone-forming therapies (25) .
Third, MCCs are endowed with antiangiogenic activity in vitro and in vivo (17) . Therefore, pauperization of MCCs might be related to the predisposition to cancer development and progression, which relies on angiogenesis and is common in acromegalic patients. In our cohort, we found no substantial relationship between MCCs and the numbers of colonic polyps. However, that might be too crude a measure of individual oncogenic potential. Future studies should assess whether MCC levels predict for cancer-associated morbidity and mortality in patients with acromegaly.
The reasons for the persistently reduced MCCs in inactive disease and after cure of acromegaly remain to be established. The MCC decrease does not appear to result from a generalized reduction in OC and BAP expression, which was affected only on monocytes and not on CD34 + cells. Therefore, the effect seems to be specific for the monocytic compartment. Monocytes and macrophages contribute to the bone marrow stem cell niche (26) , and bone marrow remodeling is accompanied by changes in macrophage populations, such as are seen in those with diabetes (27) . We detected no effect of acromegaly on circulating CD34
+ stem cells, although endothelial progenitor cells were reduced in active disease (28) . Whether bone remodeling in acromegaly involves the bone marrow stem cell niche is an interesting issue, because hematological malignancies also develop in acromegalic patients at a greater rate than in the general population (29) .
In conclusion, we recognize that most explanations for our findings are highly speculative. Nonetheless, the evidence of a sizeable defect that links bone and vascular biology and persists in inactive acromegaly and after cure is extremely intriguing and deserves future investigation. Via Giustinani 2, Padua 35128, Italy. E-mail: gianpaolofadini@ hotmail.com.
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